This page shows the latest Brukinsa news and features for those working in and with pharma, biotech and healthcare.
Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
Brukinsa was unable to demonstrate statistically significant superiority in complete response (CR) or very good partial response (VGPR) rates compared to Imbruvica. ... Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates,
However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).
mantle cell lymphoma therapy Brukinsa.
Also looking to extend into the lymphoma market is BeiGene, which recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).
China’s BeiGene has claimed its first-ever product approval in the US, getting an FDA nod for its mantle cell lymphoma (MCL) therapy Brukinsa. ... BeiGene said it will launch Brukinsa in the coming weeks, but hasn’t yet revealed its pricing plans.
More from news
Approximately 3 fully matching, plus 3 partially matching documents found.
The Fishawack Group of Companies is one of the largest independent medical communications and medical marketing specialists, with teams in...